Lin Zhang, Ph.D. in Oncology, is a Chief Technologist at the Clinical Laboratory of Sun Yat-sen University Cancer Center (SYSUCC) and a Master's Supervisor. She has served as principal investigator for one National Natural Science Foundation of China (NSFC) Young Scientists Fund, two Guangdong Provincial Natural Science Foundation projects, and two Guangdong Esophageal Cancer Institute projects. She has also participated in multiple NSFC General Programs. In the past five years, she has been responsible for a total of five funded projects and has published 31 SCI-indexed papers as (co-)first or corresponding author.

2001.09–2006.07: University of South China, Hengyang Medical School, Clinical Laboratory Medicine

2010.09–2012.12: Sun Yat-sen University, Basic Medicine, Immunology, Master's Degree

2014.09–2017.06: Sun Yat-sen University Cancer Center, Oncology, Ph.D.

Over the past five years, Dr. Zhang has been responsible for a total of 5 funded projects. She has published 31 SCI-indexed papers as (co-)first or corresponding author in the last five years, including 3 papers in journals with impact factor >10, and 13 papers with impact factor >5. Her research articles have appeared in journals such as Gut (IF=23.0), Journal of Experimental & Clinical Cancer Research (IF=11.3), NPJ Precision Oncology (IF=7.9), Journal of Translational Medicine (IF=7.4), and Cancer Cell International (IF=5.8). Selected publications are listed below.

1.  Zerong Cai; Yongqiang Zheng; Yan Hu; Mengyao Ma; Yijin Wu; Jia Liu; Luping Yang; Jiabo Zheng; Tian Tian; Peishan Hu; Zexian Liu; Lin Zhang; Ruihua Xu; Huaiqiang Ju; Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study, Gut, 2025, 10(1136).

2. Zengfei Xia; Runduan Lin; Fan Luo; Qiuyun Luo; Jing Yang; Shan Shi; Yan Li; Jiaxing Cao; Miaozhen Qiu; Lin Zhang; Wenlong Guan; Dajun Yang; Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma, NPJ Precision Oncology, 2026 May 21.

3. Qiuyun Luo; Tian Di; Miaozhen Qiu; Zengfei Xia; Yong Du; Runduan Lin; Liqiong Yang; Yuting Sun; Dajun Yang; Jian Sun; Lin Zhang; High AKAP8L expression predicts poor prognosis inesophageal squamous cell carcinoma, Cancer Cell Internationa, 2022, 22(90): 1-10.

4. Xueping Wang; Hao Huang; Lin Zhang; Yaxian Wu; Yingsheng Wen; Xuezi Weng; Qi Chen; WanliLiu; Elevated levels of neutrophil related chemokine citrullinated histone H3, interleukin-8 andC-reaction protein in patients with immune checkpoint inhibitor therapy: predictive biomarkers for response to treatment, Cancer Cell International, 2023, 23(1).

5. Chun Wu; Ruowen Xiao; Lin Zhang; Zixuan Chen; Meiyin Zhang; Jiaxin Li; Yufeng Zhou; Shuocheng Wang; Chao Jiang; Huiyun Wang; Rui Sun; Shijuan Mai; Reduced expression of UPF1 promotes tumor progression through stabilizing COX-2 mRNA in nasopharyngeal carcinoma, Frontiers In Immunology, 2025, 16(10): 1-20